Clear Cell Hidradenoma/Hidradenocarcinoma
UPDATE ON MALIGNANT ADNEXAL NEOPLASMS David S. Cassarino, M.D., Ph.D. Los Angeles Medical Center, Southern California Permanente Medical Group, Department of Pathology University of California, Irvine, Department of Dermatology CLASSIFICATION OF ADNEXAL TUMORS • Older classifications based on questionable morphologic and histochemical observations - Most of these are not specific for apocrine vs. eccrine diff’nt • Many tumors designated as eccrine or apocrine have features of the other category or features of adnexal ducts - Ducts of apocrine and eccrine nature show similar features and are essentially indistinguishable • Benign versus malignant determination is crucial for treatment and prognosis • Features such as asymmetry, infiltrative borders, increased mitoses, and necrosis favor malignancy • Atypical adnexal tumors show some, but not all, of these features • In many cases, due to limited sampling of the tumor (i.e., shave or punch biopsy), a definitive classification is not possible ◼ Such cases should be signed out descriptively, with a differential diagnosis, and complete excision recommended to obtain a definitive diagnosis • Newer immunohistochemical and molecular findings associated with particular tumors: • SOX10 in apocrine and some eccrine tumors • GATA3 in follicular, sebaceous, and apocrine tumors • MYB in adenoid cystic carcinoma, apocrine tumors • Beta-catenin overexpression in pilomatrical tumors • FXIIIa (nuclear) in sebaceous tumors • CYLD mutations in cylindroma, spiradenoma, trichoblastomas, and adenoid cystic carcinoma • HRAS, p53, RB1, APC, CDKN2A, and PTEN mutations in porocarcinoma • t(11;19) translocation in hidradenomas and hidradenocarcinomas • ETV6-NTRK3 translocation in primary cutaneous mammary analog secretory carcinoma CD117 and SOX-10 had similar overall positivity rates in benign apocrine and eccrine tumors (45% and 68% respectively), and were generally negative in other benign and malignant adnexal tumors.
[Show full text]